Arcellx reports 97% ORR and 68% CR/sCR in Phase 2 anito-cel study for RRMM

Arcellx, Inc.

Phase 2 iMMagine-1 (117 patients) showed 97% ORR and 68% CR/sCR at median 12.6 months follow-up.
No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) or immune-mediated enterocolitis.
12-month PFS rate 78.8%, OS rate 95.2%; median PFS and OS not reached.
Data to be presented at EHA2025 on June 14; commercial launch with Kite planned for 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.